The Tau protein is the major component of intracellular filaments observed in a number of neurodegenerative diseases known as tauopathies. The pathological mutant of Tau containing a prolineto-leucine mutation at position 301 (P301L) leads to severe human tauopathy. Here, we assess the impact of FK506-binding protein with a molecular mass of ∼52 kDa (FKBP52), an immunophilin protein that interacts with physiological Tau, on Tau-P301L activity. We identify a direct interaction of FKBP52 with Tau-P301L and its phosphorylated forms and demonstrate FKBP52's ability to induce the formation of Tau-P301L oligomers. EM analysis shows that Tau-P301L oligomers, induced by FKBP52, can assemble into filaments. In the transgenic zebrafish expressing the human Tau-P301L mutant, FKBP52 knockdown is sufficient to redrive defective axonal outgrowth and branching related to Tau-P301L expression in spinal primary motoneurons. This result correlates with a significant reduction of pT181 pathological phosphorylated Tau and with recovery of the stereotypic escape response behavior. Collectively, FKBP52 appears to be an endogenous candidate that directly interacts with the pathogenic Tau-P301L and modulates its function in vitro and in vivo.
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FKBP | Tau assembly | Tau-P301L dementia T au is a MAP mainly found in neurons (1, 2) , which becomes hyperphosphorylated in several neurodegenerative diseases known as tauopathies and forms intraneuronal aggregates called neurofibrillary tangles (NFTs) (3) (4) (5) . The accumulation of Tau aggregates is a multistep process that involves transient species, and growing evidence suggests that not only the NFTs but equally small oligomeric species contribute to Tau-mediated neurotoxicity (6) (7) (8) . The pathological mutant of Tau containing a proline-to-leucine mutation at position 301 (P301L) is identified in frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) (9) . Larvae of the zebrafish overexpressing the Tau-P301L mutant protein show defects in motoneuron development early on, and in this model, different Tau phosphoforms are associated with its pathological state (10) .
The FK506-binding protein with a molecular mass of ∼52 kDa (FKBP52) belongs to the immunophilin family and presents rotamase activity inhibited by FK506 binding (11) . This enzymatic activity catalyzes the isomerization of peptidyl-prolyl bonds between cis and trans conformations, and therefore influences target protein folding and function (12, 13) . FKBP52 contains additional functional domains, such as a tetratricopeptide repeat domain that serves as a binding site for molecular chaperone heat shock protein with a molecular mass of 90 kDa (14) and for which chaperone activity was observed (15) .
A novel role of FKBP52 has recently emerged because it binds directly to tubulin and induces tubulin depolymerization in vitro (16) . Biochemical characterization of FKBP52 showed that it interacts with Tau, especially its hyperphosphorylated form, and demonstrated an antagonist effect of FKBP52 on Tau's function in tubulin assembly (17) . Here, we show that FKBP52 interacts with the pathological form of Tau-P301L and induces its oligomerization and assembly into filaments. Using a transgenic zebrafish model for Tau-P301L tauopathy (10), we show that FKBP52 knockdown attenuates pathological Tau activity to reestablish axonal outgrowth and branching in defective spinal primary motoneurons. This result confirms the functional implication of FKBP52 in modulating early pathological Tau activity, at least for axonal growth and motility. We propose that FKBP52 is an important regulator of Tau conformational change and assembly, and thus may be instrumental in a therapeutic approach to the disease.
Results

FKBP52 Binds
Tau-P301L Mutant. The interaction between FKBP52 and the Tau-P301L mutant was investigated using a dot blot assay. Purified recombinant protein (2.2 μg of Tau-P301L), phosphorylated or not phosphorylated, was spotted on nitrocellulose
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and incubated with purified human FKBP52 protein. A polyclonal antibody against FKBP52 was used to monitor the amount of protein retained. As shown in Fig. 1 , the amount of FKBP52 retained by Tau-P301L was 18% (±4.5), whereas 55% (±10) of FKBP52 was retained by the same amount of the phosphorylated Tau-P301L. Thus, FKBP52 binds Tau-P301L, especially in its phosphorylated form.
FKBP52 Colocalizes with Tau-P301L in Human Neuronal Cells. In light of the emerging concept of transcellular propagation of Tau (18), we seeded SH-SY5Y neuronal cells with exogenous Tau-P301L, labeled with a cyanine (Cy) 5.5 dye, and investigated the subcellular localization of Tau-P301L and endogenous FKBP52. Fluorescence microscopy and confocal microscopy analysis showed that Tau-P301L localization was concentrated in the perinuclear region, with FKBP52 showing the intracellular colocalization of both proteins ( Fig. 2 and Fig. S1 ).
FKBP52 Induces the Formation of Tau-P301L Oligomers in Vitro.
To investigate the ability of recombinant FKBP52 to induce structural changes to Tau-P301L, we monitored the migration profile of these proteins using native gel electrophoresis. Fixed quantities of Tau-P301L were mixed with increasing amounts of FKBP52 and incubated for 30 min at 37°C. On Western blotting carried out with an anti-Tau antibody, titration of Tau-P301L with FKBP52 led to the formation of several bands having different electrophoretic mobility from those of isolated Tau-P301L, whereas no modification occurred upon exposure of Tau-P301L to control GST (Fig. 3A) . However, the same samples analyzed with an anti-FKBP52 antibody did not reveal any modification in the migration profile, suggesting a structural modification of Tau-P301L rather than a stable complex between FKBP52 and Tau-P301L. A similar pattern of oligomer formation after incubation of FKBP52 and phosphorylated Tau-P301L was detected by anti-Tau antibodies, AT8 or AT180, that recognize specific phosphorylated forms (Fig. 3B ).
Tau-P301L Can Form Paired Helical-Like Filaments When Incubated with FKBP52. To see whether the oligomers obtained could evolve into fibrillar structures, we first used light diffraction. When measuring the light scattering at 340 nm, we indeed observed a signal when mixing FKBP52 and Tau-P301L for 30 min at 37°C, but not with both proteins individually (Fig. 4A) . We analyzed the resulting samples using transmission EM, and we did observe fibrillar structures after incubation for 1 h, whereas no such structures could be found when individual protein solutions were deposited on the grid. The resulting fibers appear to be short in length and twisted, with a width of 17 nm (Fig. 4B ). As such, they resemble the filaments observed in the brains of patients with FTDP-17, most of which appear to be irregularly twisted ribbons with a width of about 15 nm (19) .
FKBP52 Knockdown Significantly Improves Axonal Growth and Branching Defects Observed in Primary Motoneurons of Tau-P301L
Transgenic Fish. To test in vivo the effect of FKBP52/Tau-P301L interaction, we used the zebrafish, cloned its full-length FKBP52 cDNA, and showed its ubiquitous expression (Fig. S2) . For functional analysis, we took advantage of the transgenic Tau-P301L zebrafish model (for convenience, we use HuC-Tau in the figures), which recapitulates several neurological defects of tauopathies, including axonal growth and branching defects seen in the spinal motoneurons (10, 20) (Fig. 5 D, F , and I). We looked specifically at the primary motoneurons that undergo axonogenesis at 17 h postfertilization (hpf), using znp1 antibodies, a pan-specific marker of primary motor axons (21) . We analyzed the first five outgrowing caudal primary motoneurons (CaP) anterior to the end of the yolk extension (Fig. 5) .
To test the role of FKBP52 in this model, we used a knockdown approach by injecting specific antisense morpholino (MO) against FKBP52. Injection of FKBP52 MO (0.4-0.6 pmol per embryo) or FKBP52 mRNA (200 pg) into WT embryos did not lead to any defect regarding the length (ability to reach their most ventral target) or the number of branches in the CaP motoneurons ( Fig. 5 E and E′) . Note that FKBP52 morphants show a slightly shorter and curved body axis (Fig. 5 A-C) but have normal neurogenesis in the spinal cord (Figs. S3 and S4 ). CaP motor axons of control 5-mismatch morphants, FKBP52 morphants, and FKBP52 mRNA were similar to WT at 48 hpf (Fig. 5  D-E′) . In the Tau-P301L transgenic model, only 57% of the CaP axons reach their most ventral target in comparison to WT ( Fig.  5I ; P < 0.05). They also show a randomized pattern of branching regarding the number of collateral branches or fascicles per axon (Fig. 5F ). However, striking changes occurred when injecting FKBP52 MO in the Tau-P301L transgenic embryos. Here, Tau-P301L/FKBP52 morphants readjust their axonal growth, whereby 78% of the CaP axons now reach their most ventral target in comparison to HuC-Tau ( Fig. 5I ; P = 0.038). In this case, no significant difference is observed between WT and Tau-P301L/ FKBP52 morphants ( Fig. 5I ; P > 0.05). They also reestablish a more close to normal distribution of collateral branching per CaP axon in comparison to Tau-P301L (t = −3.09, P = 0.01) (Fig. 5 G and G′ and Fig. S3 ). Injection of FKBP52 mRNA into Tau-P301L embryos aggravated their axonal defects. Here, only 44% of CaP motoneurons reach their most ventral target in comparison to WT ( Fig. 5I ; P < 0.01). There was also a significant difference in the collateral numbers of branches in the Tau-P301L/FKBP52 mRNA, whereby the number of CaP axons showing fewer collateral branches is significantly increased in comparison to Tau-P301L alone (Fig. 5 H and H′ and Fig. S3 ; t = −2.26, P = 0.01). To assess whether FKBP52 knockdown might modify the neuronal cell death seen in the Tau-P301L transgenic embryos, we injected FKBP52 MO and looked for cell death in the spinal cord using acridine orange (AO) labeling. No significant difference was observed in the number of AO-positive cells between Tau-P301L embryos and the Tau-P301L/FKBP52 MO siblings at 72 hpf (t = 1.15, P = 0.273; Fig. 6 ).
FKBP52 Knockdown Differentially Regulates the Levels of Pathological
Phosphorylated Forms of Tau-P301L. To investigate a change in the phosphorylation state of pathological forms of Tau, we have analyzed, after FKBP52 knockdown, two different pathological phosphorylated forms of Tau-P301L (pT181 and pT231) by Western blotting. Although there was no significant change in the overall level of expression of Tau and the pT231 pathological form, we observed a sharp decrease in the levels of the pathological phosphorylated form of Tau recognized by AT270 (epitope pT181) (Fig. 7) .
FKBP52 Knockdown Improves the Stereotypic Escape Response
Behavior in the Tau-P301L Transgenic Fish. To test whether the improvement seen in axonal branching and outgrowth after FKBP52 knockdown translates into a functional recovery, and thus better motility, we injected FKBP52 MO into Tau-P301L transgenic embryos and analyzed the escape response behavior. Due to their altered motoneuron morphology, the Tau-P301L embryos show a slow or absent movement in most of the larvae at 48 hpf (10) . Although most control fish responded to a touch stimulus with a stereotypic escape response, most mutated Tau-expressing fish showed a significantly reduced or even absent response ( Fig. 8 and Movies S1 and S2). However, the Tau-P301L/FKBP52 MO embryos showed a significant improvement in their escape response ( Fig. 8 and Movie S3). We saw that although Tau-P301L embryos move at an average speed of 527 units per second (n = 99), the speed of the Tau-P301L/FKBP52 MO embryos increased significantly to 1,750 units per second (n = 102) (t = 4.62, P = 0.001), whereas control embryos moved at an average speed of 4,147 units per second (n = 39). Discussion FKBP52/Tau-P301L Interaction Leads to Tau Oligomerization. We show that FKBP52 is able to interact physically with the Tau-P301L mutant. In this case, FKBP52 can induce a conformational change of Tau-P301L and leads to its oligomerization and filamentous assembly. This observation is in line with previous data showing important and differential effects of FKBP52 on the conformational state of other proteins, such as citrate synthase (15) and alpha-synuclein (22) . Interestingly, the Tau-P301L fibers induced by FKBP52 have an average width of 17 nm, and their ultrastructure is reminiscent of those isolated from patients with FTDP-17 (19) .
However, we failed to detect a stable Tau-P301L/FKBP52 complex, suggesting a rapid and short-lived interaction between both partners that might involve the enzymatic prolyl cis/trans isomerase of FKBP52. This activity links FKBPs to the parvulin family of isomerases, such as Pin1, the importance of which has already been reported in the pathological function of Tau (23) .
FKBP52/Tau-P301L Interaction Can Modulate Axonal Growth but Not
Cell Death at Early Stages of Tauopathy. We show that reducing FKBP52 levels can significantly enhance the growth of defective spinal primary motoneuron projections and branching, as well as improving the motility of zebrafish larvae. Moreover, the phosphorylation site pT181 is strongly decreased in FKBP52 morphants. This result suggests that reducing FKBP52 levels may delay the early progression of pathological axonal growth by acting on specific phosphorylation site(s) of Tau.
We propose a model whereby lowering the levels of FKBP52 in this transgenic model of FTDP-17 tauopathy prevents Tau-P301L from adopting a conformation prone to phosphorylation and aggregation, thereby reducing the neurotoxicity of the transgene. Given that the cell death phenotype is not modified in the morphants at these early stages, the impact of this interaction affects the defective microtubule dynamics and stability related to this pathological Tau model. However, further experiments should shed some light on the impact of FKBP52 knockdown on cell death at later stages.
We also cannot rule out the possibility that the absence of FKBP52 could lead to a release of endogenous physiological Tau, allowing it to execute its normal function of microtubule assembly. The latter hypothesis is in line with the one described previously in PC12 cells (17) .
FKBP52/Tau Interaction: The Early vs. Late Aspects of Tauopathy. The mechanism(s) linking FKBP52 and the late stage of the tauopathy process remains to be elucidated. Previously, we have shown that FKBP52 via Tau can modulate microtubule stability in vitro (16) and that levels of FKBP52 protein, at the late stages of diseases, are dramatically decreased in the brains of patients with Alzheimer's disease and FTDP-17 (24) . Here, we show, in a preliminary stage of tauopathy, that attenuating FKBP52 expression reduces the toxicity of the transgene. Based on these findings, different roles for FKBP52 can be considered. In the early development of this tauopathy, FKBP52 may induce Tau oligomer formation that can have a significant impact on axonal outgrowth and branching. However, at much later stages of the disease, given the important accumulation of hyperphosphorylated Tau and its direct oligomerization by FKBP52, the latter is more likely to be cleared, thus reducing its overall levels. Interestingly, FKBP52/Tau-P301L colabeling could be observed particularly in a perinuclear region, where a deformation of nuclear envelope was detected (Fig. S1 ), suggesting that FKBP52 could be involved in spatial sequestration of Tau-P301L. This perinuclear localization of Tau has already been observed in a similar structure called an aggresome (25, 26) . Whether FKBP52 is involved in the clearance of Tau at later stages is still to be investigated.
Further analyses of the FKBP52/Tau interaction may provide a basis for pursuing and evaluating potential therapies for Alzheimer's disease, FTDP-17, and other tauopathies by fine-tuning the balance of FKBP52.
Methods
Cloning of Human and Zebrafish FKBP52 cDNA. To clone human and zebrafish FKBP52 cDNA, RNAs were prepared from SH-SY5Y cells (human neuroblastoma cells) and from 30-hpf embryos, respectively. Additional details are provided in SI Methods.
Protein Purification. Tau with the P301L mutation was expressed in Escherichia coli and purified as described (27) . Hyperphosphorylation of Tau-P301L was performed using cytosol from the brain of a 2-mo-old rat as described previously (28) . Additional details are provided in SI Methods.
Labeling of Tau-P301L with cyanine, dot blot assays, light scattering, EM, and blue native PAGE are reported in SI Methods.
Immunocytofluorescence. Cells were grown on poly-D-lysine-coated glass coverslips for microscopy and were plated at 3.10 4 cells per well in a 12-well tissue culture plate. Subsequently, 20 μg of purified Cy5.5-labeled Tau-P301L was added to SH-SY5Y cell medium for 24 h of incubation. Information about antibodies used is provided in SI Methods.
Zebrafish Analysis. Zebrafish experiments were performed as described by Tawk et al. (29, 30) and as described in SI Methods. Fig. 7 . Effect of FKBP52 knockdown on total and phosphorylated Tau in 48-h-old transgenic zebrafish expressing Tau-P301L. Total protein extract (2.5-5 μL) was loaded on 10% SDS/PAGE and analyzed by Western blotting using specific antibodies as indicated. Ctrl, control. 
